Nimodipine | BAY-E-9736 | CAS#66085-59-4 | Calcium Channel Blocker

Nimodipine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318367

CAS#: 66085-59-4

Description: Nimodipine is a dihydropyridine calcium channel blocker originally developed for the treatment of high blood pressure. It is not frequently used for this indication, but has shown good results in preventing a major complication of subarachnoid hemorrhage (a form of cerebral hemorrhage) termed vasospasm, which is now the main use of nimodipine.

Chemical Structure

Nimodipine

CAS# 66085-59-4

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 318367
Name: Nimodipine
CAS#: 66085-59-4
Chemical Formula: C21H26N2O7
Exact Mass: 418.17
Molecular Weight: 418.440
Elemental Analysis: C, 60.28; H, 6.26; N, 6.69; O, 26.77

Price and Availability

Size	Price	Availability
500mg	USD 190	2 Weeks
1g	USD 350	2 Weeks
2g	USD 550	2 Weeks
5g	USD 950	2 Weeks
10g	USD 1450	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Nimodipine, Nimotop, Periplum, BAY E 9736, BAY-E-9736, BAYE9736

IUPAC/Chemical Name: 3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

InChi Key: UIAGMCDKSXEBJQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

SMILES Code: CC1=C(C(OCCOC)=O)C(C2=CC([N+]([O-])=O)=CC=C2)C(C(OC(C)C)=O)=C(C)N1

Appearance: Off-white to yellow solid powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Nimodipine is a dihydropyridine calcium channel blocker.
In vitro activity:	Nimodipine decreased both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. At concentrations as low as 100 nM, nimodipine significantly reduced the AHP in aging CA1 neurons. In young CA1 neurons, nimodipine decreased the AHP only at 10 microM. Reference: J Neurophysiol. 1992 Dec;68(6):2100-9. https://pubmed.ncbi.nlm.nih.gov/1491260/
In vivo activity:	Cochlear perfusion of nimodipine resulted in reversible, dose-related suppression of the compound action potential of the auditory nerve (CAP; N1-P1), a prolongation of N1 latency at suprathreshold levels, an elevated CAP threshold, a decrease in N1 latency at a constant amplitude measured at CAP threshold, a reduction in cochlear microphonics (CM), and a reduction of the negative summating potential (SP) to a point where it became positive (i.e., a reversal of SP). Reference: Hear Res. 1990 Jul;46(3):277-87. https://pubmed.ncbi.nlm.nih.gov/2168361/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	30.0	71.69
	DMF:PBS (pH 7.2) (1:4)	0.2	0.48
	DMSO	62.7	149.87
	Ethanol	43.0	102.76

Preparing Stock Solutions

The following data is based on the product molecular weight 418.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Moyer JR Jr, Thompson LT, Black JP, Disterhoft JF. Nimodipine increases excitability of rabbit CA1 pyramidal neurons in an age- and concentration-dependent manner. J Neurophysiol. 1992 Dec;68(6):2100-9. doi: 10.1152/jn.1992.68.6.2100. PMID: 1491260. 2. Honn KV, Onoda JM, Diglio CA, Carufel MM, Taylor JD, Sloane BF. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984 Jan-Mar;2(1):61-72. doi: 10.1007/BF00132307. PMID: 6543691. 3. Kuzmin A, Zvartau E, Gessa GL, Martellotta MC, Fratta W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav. 1992 Mar;41(3):497-500. doi: 10.1016/0091-3057(92)90363-k. PMID: 1533936. 4. Bobbin RP, Jastreboff PJ, Fallon M, Littman T. Nimodipine, an L-channel Ca2+ antagonist, reverses the negative summating potential recorded from the guinea pig cochlea. Hear Res. 1990 Jul;46(3):277-87. doi: 10.1016/0378-5955(90)90009-e. PMID: 2168361.
In vitro protocol:	1. Moyer JR Jr, Thompson LT, Black JP, Disterhoft JF. Nimodipine increases excitability of rabbit CA1 pyramidal neurons in an age- and concentration-dependent manner. J Neurophysiol. 1992 Dec;68(6):2100-9. doi: 10.1152/jn.1992.68.6.2100. PMID: 1491260. 2. Honn KV, Onoda JM, Diglio CA, Carufel MM, Taylor JD, Sloane BF. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984 Jan-Mar;2(1):61-72. doi: 10.1007/BF00132307. PMID: 6543691.
In vivo protocol:	1. Kuzmin A, Zvartau E, Gessa GL, Martellotta MC, Fratta W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav. 1992 Mar;41(3):497-500. doi: 10.1016/0091-3057(92)90363-k. PMID: 1533936. 2. Bobbin RP, Jastreboff PJ, Fallon M, Littman T. Nimodipine, an L-channel Ca2+ antagonist, reverses the negative summating potential recorded from the guinea pig cochlea. Hear Res. 1990 Jul;46(3):277-87. doi: 10.1016/0378-5955(90)90009-e. PMID: 2168361.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Monzani D, Genovese E, Pini LA, Di Berardino F, Alicandri Ciufelli M, Galeazzi GM, Presutti L. Nimodipine in otolaryngology: from past evidence to clinical perspectives. Acta Otorhinolaryngol Ital. 2015 Jun;35(3):135-45. Review. PubMed PMID: 26246657; PubMed Central PMCID: PMC4510937.

2: Etminan N, Macdonald RL, Davis C, Burton K, Steiger HJ, Hänggi D. Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2015;120:281-6. doi: 10.1007/978-3-319-04981-6_47. Review. PubMed PMID: 25366637.

3: Vergouwen MD, Vermeulen M, Roos YB. Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review. Lancet Neurol. 2006 Dec;5(12):1029-32. Review. PubMed PMID: 17110283.

4: Brown G, Carley S. Best evidence topic reports. Does nimodipine reduce mortality and secondary ischaemic events after subarachnoid haemorrhage? Emerg Med J. 2004 May;21(3):333. Review. PubMed PMID: 15107373; PubMed Central PMCID: PMC1726351.

5: Fritze J, Walden J. Clinical findings with nimodipine in dementia: test of the calcium hypothesis. J Neural Transm Suppl. 1995;46:439-53. Review. PubMed PMID: 8821080.

6: Mück W, Bode H. Bioanalytics of nimodipine--an overview of methods. Pharmazie. 1994 Feb-Mar;49(2-3):130-9. Review. PubMed PMID: 8171077.

7: Grobe-Einsler R. Clinical aspects of nimodipine. Clin Neuropharmacol. 1993;16 Suppl 1:S39-45. Review. PubMed PMID: 8519001.

8: de Jonge MC, Traber J. Nimodipine: cognition, aging, and degeneration. Clin Neuropharmacol. 1993;16 Suppl 1:S25-30. Review. PubMed PMID: 8518999.

9: Nimodipine for delayed cerebral ischaemia after subarachnoid haemorrhage. Drug Ther Bull. 1992 Oct 12;30(21):81-3. Review. PubMed PMID: 1425221.

10: Korolkovas A, Pancotti SL. [Nimodipine, a calcium antagonist with preferential cerebrovascular activity]. Arq Bras Cardiol. 1992 Jun;58(6):491-6. Review. Portuguese. PubMed PMID: 1340731.

11: Ernst E. Treating ischemic stroke: is nimodipine the answer? Clin Pharm. 1992 Apr;11(4):350-1. Review. PubMed PMID: 1563232.

12: Izquierdo I. Nimodipine and the recovery of memory. Trends Pharmacol Sci. 1990 Aug;11(8):309-10. Review. PubMed PMID: 2203191.

13: Adnet P, Moinardeau V, Riegel B, Lejeune JP, Fesard F, Debout J, Krivosic-Horber R. [Intravascular volume expansion and intravenous nimodipine in the treatment of cerebral vasospasm after surgical treatment of intracranial aneurysm]. Agressologie. 1990 Jun;31(6):385-8. Review. French. PubMed PMID: 2285112.

14: Bär PR, Traber J, Schuurman T, Gispen WH. CNS and PNS effects of nimodipine. J Neural Transm Suppl. 1990;31:55-71. Review. PubMed PMID: 2074438.

15: DiPalma JR. Nimodipine in subarachnoid hemorrhage. Am Fam Physician. 1989 Dec;40(6):143-5. Review. PubMed PMID: 2686374.

16: Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, Biel C, Pokrupa R, Diksic M, Meyer E, et al. The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab. 1989 Aug;9(4):523-34. Review. PubMed PMID: 2661584.

17: Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989 May;37(5):669-99. Review. PubMed PMID: 2663415.

18: Scriabine A, Schuurman T, Traber J. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J. 1989 May;3(7):1799-806. Review. PubMed PMID: 2565839.

19: Gilsbach JM. Nimodipine in the prevention of ischaemic deficits after aneurysmal subarachnoid haemorrhage. An analysis of recent clinical studies. Acta Neurochir Suppl (Wien). 1988;45:41-50. Review. PubMed PMID: 3066141.

20: Harders A, Gilsbach J. Haemodynamic effectiveness of nimodipine on spastic brain vessels after subarachnoid haemorrhage evaluated by the transcranial Doppler method. A review of clinical studies. Acta Neurochir Suppl (Wien). 1988;45:21-8. Review. PubMed PMID: 3066139.

Your view history

Nimodipine featured